Cita APA

Shiha, G., Soliman, R., Elbasiony, M., Darwish, N. H. E., & Mousa, S. A. (2019). Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study. Sci Rep.

Chicago Style Citation

Shiha, Gamal, Reham Soliman, Mohamed Elbasiony, Noureldien H. E. Darwish, i Shaker A. Mousa. "Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients With Chronic Hepatitis C Improves the Safety Profile: A Pilot Study." Sci Rep 2019.

Cita MLA

Shiha, Gamal, et al. "Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients With Chronic Hepatitis C Improves the Safety Profile: A Pilot Study." Sci Rep 2019.